RADIATION THERAPY ONCOLOGY GROUP

这是一份继续参与放射治疗的申请 肿瘤学集团改善肿瘤性质和质量的长期目标 放射治疗为患有各种形式癌症的患者提供护理。 纽约大学打算在以下两个方面加强对RTOG的承诺 耐心的积累和承担更大的领导作用。我们计划 利用我们在癌症综合管理方面的机构优势 在选定的情况下调查化疗和放射治疗的组合。 纽约大学刚刚提出了一项试验，以调查顺铂的疗效 作为头颈部晚期患者放射治疗的辅助手段 癌症。我们计划提出类似的研究，利用这一潜力 药物与放疗相结合提高治愈率 在癌症护理的各个方面，如妇科恶性肿瘤和 脑转移瘤。除了我们继续参与纽约 大学在治疗恶性肿瘤方面确立了全国领先地位 黑色素瘤应该会让我们成为最近 寻求确定最佳剂量分数的激活方案 治疗这种疾病的方法。目前有相当数量的患者 晚期转移性疾病到我们贝尔维尤医院已经取得了 美国是最近启动的治疗方案的主要贡献者 有骨转移的迹象。因此，期待活跃的团队是有坚实的基础的 参与近期和遥远的未来。 此外，纽约大学还打算开发一种基于微型计算机的通信 集团内的网络。这将提供连续、快速的交换 所有成员之间的想法以全国范围内成本的一小部分 开会。此外，该网络还将为其他网络提供模式 合作小组。纽约大学将有能力参加 几乎所有集团范围的试验。耗资数百万美元的翻修和 放射肿瘤学的改进计划正在如期进行。一个 新实验室，专门用于研究恶性肿瘤的热疗 疾病，最近已经完成，将有助于我们的参与 在RTOG热疗试验中。同样，一台新的20 mV直线加速器 应该在1983年夏天投入使用，并提供更多的光子和 电子处理能力。

This is an application to continue participation in the Radiation Therapy Oncology Group's long-term objective of improving the nature and quality of radiation therapy care for patients who suffer from various forms of cancer. NYU intends to intensify its commitment to the RTOG both in terms of patient accrual and in assuming a greater role of leadership. We plan to exploit our institutional strength in multimodality management of cancer to investigate chemotherapy-radiotherapy combinations in selected situations. NYU has just proposed a trial to investigate the efficacy of cis-platinum as an adjuvant to radiotherapy for patients having advanced head and neck cancer. We plan to propose similar studies, utilizing the potential enhancement of the therapeutic ratio by combining drugs with radiotherapy in such diverse aspects of cancer care as gynecologic malignancies and brain metastases. In addition to our continued participation New York University's established national leadership in the treatment of malignant melanoma should permit us to become a leading contributor to the recently activated protocol seeking to define the optimal dose fraction for treatment of this disease. The substantial number of patients that present with advanced metastatic disease to our Bellevue Hospital has already made us the leading contributor to the recently activated protocol for therapy of bone metastases. Thus, there is a firm basis to expect active group participation in the immediate and distant future. Furthermore, NYU intends to develop a micro-computer based communications network within the group. This will provide continuous, rapid interchange of ideas between all members at a fraction of the cost of a nationwide meeting. In addition, this network will provide a model for other cooperative groups. NYU will have the capability of participating in virtually all groupwide trials. A multimillion dollar renovation and improvement program in radiation oncology is progressing on schedule. A new laboratory, solely dedicated to the study of hyperthermia in malignant disease, recently has been completed and will facilitate our participation in RTOG hyperthermia trials. Similarly, a new 20 MV linear accelerator should be operational by summer 1983 and provide increased photon and electron treatment capability.